Skip Navigation



Annals of Oncology Advance Access published online on June 25, 2009
Annals of Oncology, doi:10.1093/annonc/mdp231
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de la Fouchardière, C.
Right arrow Articles by Pujade-Lauraine, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by de la Fouchardière, C.
Right arrow Articles by Pujade-Lauraine, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE

C. de la Fouchardière1, R. Largillier2, Y. Goubely3, A.-C. Hardy-Bessard4, B. Slama5, J. Cretin6, H. Orfeuvre7, D. Paraiso8, T. Bachelot1,* and E. Pujade-Lauraine9,10

1 Department of Medical Oncology, Centre Léon Bérard, Lyon
2 Department of Medical Oncology, Centre Azuréen de Cancérologie, Mougins
3 Department of Medical Oncology, Institut Sainte-Catherine, Avignon
4 Department of Medical Oncology, Clinique Armoricaine de Radiologie, Saint-Brieuc
5 Department of Medical Oncology, Hôpital Henri Duffaut, Avignon
6 Department of Medical Oncology, Clinique Bonnefon, Alès
7 Department of Medical Oncology, Hôpital Fleyriat, Bourg-en-Bresse
8 Department of Medical Oncology, Centre Hospitalier de l'Agglomération Montargeoise, Amilly
9 Department of Medical Oncology, Université Paris-Descartes, Paris
10 Hôpital Hôtel-Dieu, Paris, France

* Correspondence to: Dr T. Bachelot, Département d'Oncologie Médicale, Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon Cedex, France. Tel: +33-0-4-78-78-26-54; Fax: +33-0-4-78-78-27-14; E-mail: bachelot{at}lyon.fnclcc.fr

Background: This phase II study evaluated the clinical benefit of pegylated liposomal doxorubicin (PLD) and docetaxel (Taxotere) as first-line therapy for metastatic breast cancer (MBC).

Patients and methods: MBC patients were enrolled to receive six cycles of PLD 35 mg/m2 (day 1) and docetaxel 40 mg/m2 (days 1 and 15), every 28 days (group A). Because of unacceptable toxic effects, doses were modified to PLD 30 mg/m2 (day 1) and docetaxel 75 mg/m2 (day 2), every 3 weeks (group B). The primary end point was clinical benefit.

Results: Sixty-seven patients were included (group A, 53; group B, 14). In both groups, the median number of cycles delivered was 4 and the overall dose intensity was 82% for docetaxel and 71% for PLD. In group A, main toxic effects were hematologic, palmar–plantar erythrodysesthesia (PPE), and stomatitis. In group B, higher rates of grade 3–4 PPE, febrile neutropenia, and hematologic toxic effects were reported. The rate of clinical benefit was 47%. Among patients with a measurable disease, 49% achieved a partial response, 27% had a stable disease, and 13% progressed, according to RECIST criteria.

Conclusion: The combination of PLD and docetaxel delivered at planned doses in this study yields unacceptable toxicity and should not be used routinely in patients with MBC.

docetaxel, first-line chemotherapy, metastatic breast cancer, pegylated liposomal doxorubicin

Received for publication October 7, 2008. Revision received March 10, 2009. Accepted for publication March 16, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.